Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
JNJ-8543 by Johnson & Johnson for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
JNJ-8543 is under clinical development by Johnson & Johnson and currently in Phase I for Chronic Lymphocytic Leukemia (CLL). According...
JNJ-8543 by Johnson & Johnson for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma): Likelihood of Approval
JNJ-8543 is under clinical development by Johnson & Johnson and currently in Phase I for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma). According...
JNJ-8543 by Johnson & Johnson for Follicular Lymphoma: Likelihood of Approval
JNJ-8543 is under clinical development by Johnson & Johnson and currently in Phase I for Follicular Lymphoma. According to GlobalData,...
JNJ-8543 by Johnson & Johnson for Splenic Marginal Zone B-Cell Lymphoma: Likelihood of Approval
JNJ-8543 is under clinical development by Johnson & Johnson and currently in Phase I for Splenic Marginal Zone B-Cell Lymphoma....